Anti-Human PD-L1 (Atezolizumab) - APC
Code | Size | Price |
---|
LEI-LT1751-50ug | 50 ug | £250.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Human
Antibody Isotype: Human IgG
Antibody Clonality: Monoclonal
Antibody Clone: Atezolizumab
Regulatory Status: RUO
Target Species: Human
Applications:
- Flow Cytometry
- Western Blot (WB)
Shipping:
2-8°C
Storage:
This Allophyc°Cyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze.
Further Information
Antigen Distribution:
PD-L1 is present on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
Allophycocyanin (APC)
Format:
This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Unknown
Long Description:
PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.
Target:
PD-L1
References
1. Ardolino, M. et al. (2018) J Clin Invest. 128(10):4654-4668. PubMed
2. Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117.
3. Freeman, G. et al. (2000) J. Exp. Med. 192:1027.